M&A Deal Summary

ZOLL Medical Acquires Itamar Medical

On September 13, 2021, ZOLL Medical acquired medical products company Itamar Medical for 538M USD

Acquisition Highlights
  • This is ZOLL Medical’s 9th transaction in the Medical Products sector.
  • This is ZOLL Medical’s largest (disclosed) transaction.
  • This is ZOLL Medical’s 2nd transaction in Israel.

M&A Deal Summary
Date 2021-09-13
Target Itamar Medical
Sector Medical Products
Buyer(s) ZOLL Medical
Deal Type Add-on Acquisition
Deal Value 538M USD
Advisor(s) Piper Sandler & Co. (Financial)
Latham & Watkins
Goldfarb Seligman (Legal)

Target

Itamar Medical

Caesarea, Israel
website
Itamar Medical is a medical device company which develops, markets and sells diagnostic medical devices based on the PAT™ (Peripheral Arterial Tone) signal. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. Itamar Medical was founded in 1997 and is based in Caesarea, Israel.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ZOLL Medical

Chelmsford, Massachusetts, United States

website

Category Company
Sector Medical Products
DESCRIPTION

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

DEAL STATS #
Overall 13 of 13
Sector (Medical Products) 9 of 9
Type (Add-on Acquisition) 13 of 13
Country (Israel) 2 of 2
Year (2021) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-12 Respicardia

Minnetonka, Minnesota, United States

Respicardia is a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea. CSA is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias. Respicardia was founded in 2006 and is based in Minnetonka, Minnesota.

Buy -
Mergr

Product

Company

Legal